Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dan Zabrowski, Thomas Schinecker, Charles Dadswell

Premium

Dan Zabrowski will head Roche's new sequencing unit as part of a reorganization by the company that is dissolving its Applied Science unit of the Diagnostic division (see IS 4/23/2012). Zabrowski was previously the head of Roche Applied Science. Also, as part of the reorganization, Thomas Schinecker will become general manager of Roche Diagnostics Germany in June. Previously, he was president of Roche Sequencing Solutions.


Illumina has named Charles Dadswell senior vice president and general counsel, replacing Christian Cabou, who has retired. Dadswell will be responsible for all legal and intellectual property matters and will also serve as secretary to Illumina's board of directors. He joins Illumina from BioMérieux, where he served as vice president and general counsel for North and Latin America and corporate director of global intellectual property. Previously, he was general counsel at BioDelivery Sciences International, a specialty pharmaceutical company. He holds an LLM in patent law and trade regulation from George Washington University Law School, a JD from the Thomas M. Cooley Law School, and a BS from Ferris State University.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.